797 related articles for article (PubMed ID: 22943064)
21. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
22. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
23. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
25. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
26. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan.
Peng CT; Chow KC; Chen JH; Chiang YP; Lin TY; Tsai CH
Eur J Haematol; 2003 Jun; 70(6):392-7. PubMed ID: 12756022
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients.
Ooi GC; Khong PL; Chan GC; Chan KN; Chan KL; Lam W; Ng I; Ha SY
Br J Haematol; 2004 Feb; 124(3):385-90. PubMed ID: 14717788
[TBL] [Abstract][Full Text] [Related]
28. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of heart and liver iron deposition status in patients with β- thalassemia intermedia and major with MRI T2* technique].
Li CG; Liu SX; Mai HR; Wang Y; Wen FQ; Liu RY; Zhang XH; Chu WC; Au WY
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Feb; 14(2):110-3. PubMed ID: 22357467
[TBL] [Abstract][Full Text] [Related]
30. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
31. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores.
Tony S; Daar S; Elshinawy M; Al-Zadjaly S; Al-Khabori M; Wali Y
Pediatr Hematol Oncol; 2012 Sep; 29(6):579-84. PubMed ID: 22839111
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
33. T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients.
Hashemieh M; Azarkeivan A; Akhlaghpoor S; Shirkavand A; Sheibani K
Arch Iran Med; 2012 Feb; 15(2):91-4. PubMed ID: 22292579
[TBL] [Abstract][Full Text] [Related]
34. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
Perifanis V; Christoforidis A; Vlachaki E; Tsatra I; Spanos G; Athanassiou-Metaxa M
Int J Hematol; 2007 Dec; 86(5):385-9. PubMed ID: 18192103
[TBL] [Abstract][Full Text] [Related]
35. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
[TBL] [Abstract][Full Text] [Related]
36. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
37. Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.
Piga A; Longo F; Musallam KM; Cappellini MD; Forni GL; Quarta G; Chiavilli F; Commendatore F; Mulas S; Caruso V; Galanello R
Br J Haematol; 2013 Jun; 161(6):872-83. PubMed ID: 23600689
[TBL] [Abstract][Full Text] [Related]
38. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
[TBL] [Abstract][Full Text] [Related]
39. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
40. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major.
Papakonstantinou O; Alexopoulou E; Economopoulos N; Benekos O; Kattamis A; Kostaridou S; Ladis V; Efstathopoulos E; Gouliamos A; Kelekis NL
J Magn Reson Imaging; 2009 Apr; 29(4):853-9. PubMed ID: 19306409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
